Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs TransMedics Group Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.8× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 882,859). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Innov-100 0DTE Covered Call Strat ETF for 57 Days and TransMedics Group Inc for 24 Days on average.
| QDTE | TMDX | |
|---|---|---|
Market Cap | $962.24M | $2.74B |
Volume | 882,859 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $150.42 |
52-Week Low | $26.85 | $61.99 |
Typical Hold Time | 57 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.50, down 1.3% today amid bearish technical signals. The ETF generates weekly income through covered call strategies on Nasdaq-100 components, with recent distributions ranging from $0.11-$0.28. Technical indicators show mixed signals with overall bearish momentum, while fundamental data remains limited for this specialized income-focused product.
The outlook remains cautious as declining volatility pressures distribution yields, with recent payouts suggesting a more sustainable 24-31% annualized yield versus the trailing 43%. Key risks include NAV erosion from return of capital and underperformance in bull markets due to capped upside potential from daily call writing strategies.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
